欧洲皮肤黑色素瘤跨学科共识指南(2019更新)第二部分:治疗
该指南由欧洲皮肤病论坛、欧洲皮肤肿瘤协会和EORTC的多学科专家共同制定,基于系统文献综述和专家经验,对皮肤黑色素瘤的治疗提出推荐。推荐包括手术切缘1-2 cm、前哨淋巴结活检的指征、III/IV期患者辅助治疗首选抗PD-1或BRAF/MEK抑制剂(BRAF突变者),以及远处转移的系统治疗选择。
要点
- 皮肤黑色素瘤切除安全切缘为1-2 cm。
- 肿瘤厚度≥1.0 mm或≥0.8 mm伴组织学危险因素者应行前哨淋巴结活检分期。
- III/IV期辅助治疗首选抗PD-1(不限突变状态)或达拉非尼联合曲美替尼(BRAF突变者)。
核心结论
- III/IV期黑色素瘤辅助治疗首选抗PD-1(不限突变状态)或达拉非尼联合曲美替尼(BRAF突变者)。
- 远处转移者需系统治疗,一线可考虑PD-1抗体单药或联合CTLA-4抗体免疫治疗;BRAF-V600 E/K突变者可一线用BRAF/MEK抑制剂。
研究设计与样本
- 由欧洲皮肤病论坛、欧洲皮肤肿瘤协会和EORTC多学科专家协作,基于系统文献综述和专家经验制定共识指南。
主要发现
- 皮肤黑色素瘤切除安全切缘为1-2 cm。
- 前哨淋巴结活检推荐用于肿瘤厚度≥1.0 mm或≥0.8 mm伴组织学危险因素者,但尚无明确生存获益。
- III/IV期辅助治疗首选抗PD-1(不限突变状态)或达拉非尼联合曲美替尼(BRAF突变者)。
- 远处转移一线免疫治疗可选PD-1抗体单药或联合CTLA-4抗体;BRAF-V600 E/K突变者可一线用BRAF/MEK抑制剂。
- 对免疫治疗原发耐药且BRAF-V600 E/K突变者,二线可提供BRAF/MEK抑制剂治疗。
关键数值与推荐
- 皮肤黑色素瘤切除安全切缘为1-2 cm。
- 前哨淋巴结活检指征:肿瘤厚度≥1.0 mm或≥0.8 mm伴组织学危险因素。
- III/IV期辅助治疗首选抗PD-1(不限突变状态)或达拉非尼联合曲美替尼(BRAF突变者)。
- 远处转移一线免疫治疗可选PD-1抗体单药或联合CTLA-4抗体;BRAF-V600 E/K突变者可一线用BRAF/MEK抑制剂。
- 对免疫治疗原发耐药且BRAF-V600 E/K突变者,二线可提供BRAF/MEK抑制剂治疗。
临床怎么用
- III/IV期患者的治疗决策应由跨学科肿瘤团队(Tumor Board)主要制定。
- 皮肤黑色素瘤手术切除应保证1-2 cm安全切缘。
- 符合指征者行前哨淋巴结活检分期。
- III/IV期辅助治疗根据突变状态选择抗PD-1或达拉非尼联合曲美替尼。
- 远处转移者根据突变状态和既往治疗选择免疫治疗或BRAF/MEK抑制剂。
局限性
- 前哨淋巴结活检尚无明确生存获益。
- III/IV期黑色素瘤系统治疗领域快速变化,推荐可能近期更新。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A unique collaboration of multidisciplinary experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization for Research and Treatment of Cancer (EORTC) was formed to make recommendations on cutaneous melanoma diagnosis and treatment, based on systematic literature reviews and the experts' experience. Cutaneous melanomas are excised with 1- to 2-cm safety margins. Sentinel lymph node dissection shall be performed as a staging procedure in patients with tumour thickness ≥1.0 mm or ≥0.8 mm with additional histological risk factors, although there is as yet no clear survival benefit for this approach. Therapeutic decisions in stage III/IV patients should be primarily made by an interdisciplinary oncology team ("Tumor Board"). Adjuvant therapies in stage III/IV patients are primarily anti-PD-1, independent of mutational status, or dabrafenib plus trametinib for BRAF-mutant patients. In distant metastasis, either resected or not, systemic treatment is indicated. For first-line treatment, particularly in BRAF wild-type patients, immunotherapy with PD-1 antibodies alone or in combination with CTLA-4 antibodies shall be considered. In particular scenarios for patients with stage IV melanoma and a BRAF-V600 E/K mutation, first-line therapy with BRAF/MEK inhibitors can be offered as an alternative to immunotherapy. In patients with primary resistance to immunotherapy and harbouring a BRAF-V600 E/K mutation, this therapy shall be offered in second-line. Systemic therapy in stage III/IV melanoma is a rapidly changing landscape, and it is likely that these recommendations may change in the near future.
引用
- Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2019. Eur J Cancer. 2019. PMID: 31866016. doi:10.1016/j.ejca.2019.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。